Clinical trial
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for…
NCT00139282 · Genaera Corporation, Industry · Terminated
Key facts
| NCT number | NCT00139282 |
|---|---|
| Title | A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration |
| Official title | A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration |
| Lead sponsor | Genaera Corporation, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | "Wet" Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Squalamine Lactate |
| Start date | Jun 1, 2005 |
| First posted | Aug 31, 2005 |
| Last update posted | Nov 28, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: